Jiang Dapeng, Yang Shulong, Gao Peng, Zhang Yubo, Guo Tieyun, Lin Houwei, Geng Hongquan
Department of Pediatric Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 KongJiang Road, Shanghai, 200092, China.
Department of Pediatric Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Cell Tissue Res. 2015 Dec;362(3):587-95. doi: 10.1007/s00441-015-2250-4. Epub 2015 Jul 30.
Transplantation of ligament-tissue-derived stem cells has become a promising approach in the repair of injured ligament. Neovascularization plays an important role in ligament healing and remodeling. Recently, human umbilical-cord-blood-derived CD34+ cells have been reported to contribute to neoangiogenesis. Therefore, we performed a series of experiments to test our hypothesis that the combination of medial collateral ligament stem cells (MCL-SCs) and umbilical-cord-blood-derived CD34+ cells has synergistic effects on tendon healing. MCL-SCs and umbilical-cord-blood-derived CD34+ cells were isolated and cultured. Rat MCL injury was treated by MCL-SCs and/or CD34+ cells. Response to the cell therapy was assessed by gross observation, histological evaluation and biomechanical testing at 2 and 4 weeks after each treatment. Although each cell therapy group induced macroscopic and morphological recovery in healing MCLs, the combined use of MCL-SCs/CD34+ cells led to further improvement in healing quality. Capillary density was significantly higher in the CD34+ cell transplantation groups than in the other groups at week 2. Biomechanical testing demonstrated that the failure load of the healing ligament was greatest in the combination therapy group. The combination of MCL-SCs and CD34+ cells as a cell therapeutic thus enhances healing and restores biomechanical function toward normal after MCL injury. The findings obtained in our study suggest that the combination of MCL-SCs and CD34+ cells transplantation represents a promising strategy for ligament injury.
韧带组织来源干细胞移植已成为修复受损韧带的一种有前景的方法。新生血管形成在韧带愈合和重塑中起重要作用。最近，有报道称人脐带血来源的CD34+细胞有助于新生血管生成。因此，我们进行了一系列实验来验证我们的假设，即内侧副韧带干细胞（MCL-SCs）与脐带血来源的CD34+细胞联合应用对肌腱愈合具有协同作用。分离并培养了MCL-SCs和脐带血来源的CD34+细胞。用MCL-SCs和/或CD34+细胞治疗大鼠内侧副韧带损伤。在每次治疗后2周和4周，通过大体观察、组织学评估和生物力学测试来评估细胞治疗的反应。尽管每个细胞治疗组均诱导愈合中的内侧副韧带出现宏观和形态学恢复，但联合使用MCL-SCs/CD34+细胞可进一步提高愈合质量。在第2周时，CD34+细胞移植组的毛细血管密度显著高于其他组。生物力学测试表明，联合治疗组愈合韧带的破坏负荷最大。因此，MCL-SCs和CD34+细胞联合作为细胞治疗可促进内侧副韧带损伤后的愈合并使生物力学功能恢复至正常。我们研究中获得的结果表明，MCL-SCs和CD34+细胞联合移植是治疗韧带损伤的一种有前景的策略。
